Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06990659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Study acronym: CHOC
StatusRecruiting
PhaseNot applicable
Started2025-12-18
View on ClinicalTrials.gov ↗

Amendment history

2026-07-15
2 amendments v4-v5
2 re-verifications since 2026-06-30, no change to tracked fields
2026-06-25
Study Identification, Study Status, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v3
Trial sites expanded: 14 → 19 locations
Eligibility criteria+306 characters
[...] for the Study of the Liver (2024) or histologically proven. Patient with HCC or iCCA naiveeligible tofor intra-arterial treatment. HCC (transarterial chemoembolization [TACE] or iCCAtransarterial mayradioembolization have been previously treated[TARE]), with no prior intra-arterial treatment of the same type as the one planned in the trial: no prior TACE for patients included for TACE; no prior TARE for patients included for TARE. Prior intra-arterial treatment of the other type is allowed (prior TACE before TARE, or prior TARE before TACE). Prior non-intra-arterial therapies. Othertreatments [...]
Secondary endpoints27 entries, revised
Comparing the organizations (Comfort and satisfactionPain)
2026-03-09
Not Yet Recruiting→Recruiting Study Identification, Study Status, Study Description, Conditions, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-10-31→2027-12-17
Completion date2028-06-30→2028-12-17
Start dateestimated 2025-12-01→confirmed 2025-12-18
Study sites16→14
Eligibility criteria+390 characters
Inclusion Criteria: Age ≥ 18 years HCC or CCiiCCA diagnosed according to the criteria of the European Associa [...] Study of the Liver (2024) or histologically proven. HCC or CCiiCCA naive to intra-arterial treatment. HCC or iCCA may have been previously treated with other non-intra-arter [...] eviously treated but not with intra-arterial therapy. If HCC ou iCCA treatment is proposed at a Multidisciplinary Consultation M [...] invasion Uni-lobar tumor invasion (except for centrohepatic CCiiCCA) Total bilirubin < 20 mg/l (or 35 µmol/L) Patient affiliate [...] morphological elements of predictable technical difficulty Pl [...] [...]
Secondary endpoints26 to 27 entries
4. Adoption (quantitative) ScopeReach (Quantitative) ScopeReach (Qualitative for centers) ScopeReach (Qualitative for patients) Ambulatory pathway failure
Study title+14 characters
Outpatient Versus Inpatient Care Pathway for Patients Treated Intra-arteriallyarterial forTreatment of Primary Liver Cancer (CHOC)
2025-11-18
Study Status v1
Primary completion date2027-05-31→2027-10-31
Completion date2028-05-31→2028-06-30
Start date2025-06-01→2025-12-01
2025-05-21
Original filing
Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)). Patients are followed for 7 months to assess patient satisfaction, safety and clinical outcomes. A qualitative implementation study and a medico-economic evaluation (cost analysis and 5-years budget impact analysis) are embedded to assess acceptability, adoption, feasability, and sustainability and to inform scaling.
Trial Details
NCT Number NCT06990659
Lead Sponsor University Hospital, Angers
Collaborators: Université Paris Cité
Conditions Hepato Cellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma
Enrollment 206 participants
Start Date 2025-12-18
Primary Completion 2027-12-17 (estimated)
Study Completion 2028-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-17